Safety study of dostarlimab for advanced endometrial cancer in India
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests the safety of the drug dostarlimab for people with advanced or recurrent endometrial cancer that has come back after initial treatment. It is for adults in India whose cancer cannot be cured by surgery or radiation alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced (Stage III or IV) or recurrent endometrial cancer that is unlikely to be cured by surgery or radiation.
- Your doctor has confirmed you are a good candidate for dostarlimab based on its approved use.
- You have not had more than one recurrence of endometrial cancer.
- You have not had prior treatment with a similar type of immunotherapy (like an anti-PD-1 or anti-PD-L1 drug).
- You must be willing to use contraception if you could become pregnant, and have a negative pregnancy test before starting.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a drug called dostarlimab for people in India whose endometrial cancer has come back or spread and has a specific genetic profile (dMMR/MSI-H). It may be an option if platinum-based chemotherapy stopped working.
This trial tests a combination of the immunotherapy drug dostarlimab with standard chemotherapy (carboplatin and paclitaxel) for people with advanced or recurrent endometrial cancer that has a specific genetic feature called dMMR or MSI-H. The goal is to see if this combination works better than chemotherapy alone.
This trial tests a new maintenance treatment (GSK5733584) for women with a certain type of endometrial cancer (MMRp or MSS). It's for people whose cancer has not grown after initial chemo and immunotherapy, and they will continue immunotherapy as part of the study.
This trial tests the drug dostarlimab, alone or with other therapies, given before surgery in people with advanced stage 3 or 4 endometrial cancer. The goal is to see if these treatments shrink the cancer and improve outcomes before the planned operation.
This Phase 1 trial studies how safe and tolerable it is to add dostarlimab (an immunotherapy) to standard chemo and radiation, followed by more chemotherapy, for stage IIIC endometrial cancer that has spread to lymph nodes. It aims to see whether this combination can be given safely soon after surgery.
This trial tests the drug dostarlimab for patients with early-stage endometrial cancer that is MMR deficient. It aims to see if the treatment is safe and effective for those who want to preserve their uterus or cannot have surgery.
Hear when a new Neoplasms, Endometrial trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.